Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Tax Provisions (2023 - 2025)

Spero Therapeutics' Tax Provisions history spans 3 years, with the latest figure at $261000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions rose 190.0% year-over-year to $261000.0; the TTM value through Dec 2025 reached $261000.0, down 89.95%, while the annual FY2025 figure was $261000.0, N/A changed from the prior year.
  • Tax Provisions reached $261000.0 in Q4 2025 per SPRO's latest filing, up from -$290000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $2.2 million in Q3 2023 to a low of -$290000.0 in Q4 2024.
  • Average Tax Provisions over 3 years is $571800.0, with a median of $290000.0 recorded in 2024.
  • Peak YoY movement for Tax Provisions: tumbled 174.94% in 2024, then soared 190.0% in 2025.
  • A 3-year view of Tax Provisions shows it stood at $387000.0 in 2023, then tumbled by 174.94% to -$290000.0 in 2024, then skyrocketed by 190.0% to $261000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Tax Provisions are $261000.0 (Q4 2025), -$290000.0 (Q4 2024), and $290000.0 (Q3 2024).